2018 Large Cap Biopharmaceutical Stocks : First Quarter Performance Update

http://lesmasphotos.com/liams-baby-shoot/?share=twitter 2018 Large Cap Biopharmaceuticals – Performance Compared to ETFs

It has been a rough start for large cap biopharmaceutical stocks but the ETFs (FBT) and (XBI) still outperformed the SPY YTD and over 12 months. Most Individual stocks lagged unless you owned http://burlingtoncarshow.ca/?wordfence_lh=1 Abbvie (ABBV) or Vertex Pharmaceuticals (VRTX). Here are some key takeaways:

  • Buy the worst performers on technicals and valuations? BIIB CELG REGN.
  • Look at most stable stocks with good performance and dividends: BMY GILD.
  • Fidelity biotechnology fund (FBIOX) is outperforming the large cap weighted (IBB).
  • Over 12 months the FBT and XBI are the top performing ETFs.
  • Double bottom in key indices after Q1 could be a  buy signal.
Ticker Price 2017 Market P/S % Perform % Perform
3/30/2018 Rev$B Cap $B 12 mos YTD 2018 YTD
3/30/2018
source site Abbvie ABBV 94.65 28.22 151.29 5.36 43.9 -2.13
Alexion ALXN 111.46 3.55 25.48 7.17 -7.67 -6.8
Amgen AMGN 170.48 22.85 127.66 5.59 4.55 -1.97
Biogen BIIB 273.82 12.27 60.55 4.93 1.97 -14
Bristol MyersSquibb BMY 63.25 20.78 106.41 5.12 14.2 3.16
Celgene CELG 89.21 13 68.63 5.28 -28.7 -14.5
Gilead Sci GILD 75.39 26.11 102.46 3.92 12.09 5.23
Merck MRK 54.47 40.12 148.81 3.71 -2.1 -13.4
Regeneron REGN 344.36 5.87 37.82 6.44 -12.6 -8.41
Vertex VRTX 162.98 2.49 42.71 17.16 50.9 8.79
XBI 87.73 25.8 3.37
FBT  132.9 26.5 6.69
IBB 106.74 8.76 0
FBIOX 226.14 11.7 3.07
XLV 81.4 9.17 -1.55

 

 

No comments yet.

Leave a Reply